- Home
- PTNM vs ENGN Comparison
PTNM vs ENGN Comparison
Compare PTNM & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTNM
- ENGN
- Stock Information
- Founded
- PTNM 2013
- ENGN 1999
- Country
- PTNM Hong Kong
- ENGN Canada
- Employees
- PTNM N/A
- ENGN N/A
- Industry
- PTNM
- ENGN
- Sector
- PTNM
- ENGN
- Exchange
- PTNM Nasdaq
- ENGN Nasdaq
- Market Cap
- PTNM 320.2M
- ENGN 349.1M
- IPO Year
- PTNM 2025
- ENGN N/A
- Fundamental
- Price
- PTNM $10.39
- ENGN $7.75
- Analyst Decision
- PTNM
- ENGN Buy
- Analyst Count
- PTNM 0
- ENGN 7
- Target Price
- PTNM N/A
- ENGN $20.29
- AVG Volume (30 Days)
- PTNM 3.3M
- ENGN 262.4K
- Earning Date
- PTNM 01-01-0001
- ENGN 09-11-2025
- Dividend Yield
- PTNM N/A
- ENGN N/A
- EPS Growth
- PTNM N/A
- ENGN N/A
- EPS
- PTNM 0.03
- ENGN N/A
- Revenue
- PTNM $9,693,445.00
- ENGN N/A
- Revenue This Year
- PTNM N/A
- ENGN N/A
- Revenue Next Year
- PTNM N/A
- ENGN N/A
- P/E Ratio
- PTNM $365.42
- ENGN N/A
- Revenue Growth
- PTNM 9.87
- ENGN N/A
- 52 Week Low
- PTNM $0.98
- ENGN $2.65
- 52 Week High
- PTNM $14.79
- ENGN $11.00
- Technical
- Relative Strength Index (RSI)
- PTNM N/A
- ENGN 71.29
- Support Level
- PTNM N/A
- ENGN $6.07
- Resistance Level
- PTNM N/A
- ENGN $8.35
- Average True Range (ATR)
- PTNM 0.00
- ENGN 0.59
- MACD
- PTNM 0.00
- ENGN 0.07
- Stochastic Oscillator
- PTNM 0.00
- ENGN 75.26
About PTNM Pitanium Limited Class A Ordinary shares
Pitanium Ltd is a retailer in Hong Kong focusing on the sale of its proprietary brand of skincare and personal care products, especially haircare products, namely PITANIUM and BIG PI online and offline with six retail stores situated in Prime shopping destinations in Hong Kong. The company emphasizes product design and development with an in-house product development team working closely with its original equipment manufacturing (OEM) and original design manufacturing (ODM) suppliers.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.